Skip to main content
. 2007 May 25;6(Suppl 4):19–25. doi: 10.1111/j.1524-6175.2004.03564.x

Figure 2.

Figure 2

Clinical events in The African American Study of Kidney Disease and Hypertension trial. Data represent reductions in risk of the composite clinical outcomes (glomerular filtration rate declines of ≥50% from baseline or 25 mL/min per 1.73 m2, end‐stage renal disease, or death). Source: JAMA. 2002;288:2421–2431 23